Skip to main content
Past Event

Reining in prescription drug prices

Past Event

Paper: Framework for negotiation in Part D of Medicare

Paper: Framework for negotiation in Part D of Medicare
Play Video
Now Playing

Paper: Framework for negotiation in Part D of Medicare

Paper: Can importation address high generic drug prices?
Play Video
Now Playing

Paper: Can importation address high generic drug prices?

Paper: Removing barriers to competition in pharmaceutical markets
Play Video
Now Playing

Paper: Removing barriers to competition in pharmaceutical markets

Panel: The politics of prescription drugs
Play Video
Now Playing

Panel: The politics of prescription drugs

Spending on prescription drugs in the U.S. has been increasing rapidly over the past few years, fueled by the introduction of expensive new drugs and price hikes on existing drugs. While the public demands new and better cures, polls suggest that they also overwhelmingly want the government to rein in prices. With prescription drug spending now accounting for roughly $1 of every $6 spent on health care, controlling pharmaceutical spending is also important to controlling health spending more broadly. How can we slow the pace of prescription drug increases without discouraging innovation and discovery?

On May 2, the Hutchins Center on Fiscal and Monetary Policy and the Center for Health Policy at Brookings hosted a forum on policies to lower prescription drug prices. The event began with presentations of three proposals aimed at reducing prescription drug prices, followed by a panel discussion on the proposals from a variety of perspectives. The event closed with a panel on the politics of prescription drug reform.

Read the policy brief: Ten challenges in the prescription drug market—and ten solutions

Agenda

Opening remarks

Paper: Framework for negotiation in Part D of Medicare

Richard Frank

Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy - Harvard Medical School

Richard J. Zeckhauser

Frank P. Ramsey Professor of Political Economy - Harvard Kennedy School of Government

Paper: Can importation address high generic drug prices?

Thomas Bollyky

Senior Fellow for Global Health, Economics, and Development - Council on Foreign Relations (CFR)

Aaron Kesselheim

Associate Professor of Medicine - Brigham and Women’s Hospital and Harvard Medical School

Paper: Removing barriers to competition in pharmaceutical markets

Fiona Scott Morton

Theodore Nierenberg Professor of Economics - Yale School of Management

Panel: Perspectives from the field

Troyen Brennan

Executive Vice President and Chief Medical Officer - CVS Health

Jennifer Bryant

Senior Vice President, Policy and Research - Pharmaceutical Research and Manufacturers of America (PhRMA)

Steven Pearson

President - Institute for Clinical and Economic Review (ICER)

Rachel Sachs

Associate Professor of Law - Washington University School of Law

Panel: The politics of prescription drugs

More Information

To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.

Get a weekly events calendar from Brookings